Mabpharm Past Earnings Performance
Past criteria checks 0/6
Mabpharm's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 34.8% per year.
Key information
-8.5%
Earnings growth rate
-0.5%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 34.8% |
Return on equity | -63.3% |
Net Margin | -272.9% |
Next Earnings Update | 26 Mar 2024 |
Recent past performance updates
Recent updates
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09Revenue & Expenses BreakdownBeta
How Mabpharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 71 | -194 | 131 | 129 |
31 Mar 23 | 64 | -202 | 125 | 139 |
31 Dec 22 | 56 | -211 | 119 | 148 |
30 Sep 22 | 43 | -237 | 119 | 163 |
30 Jun 22 | 30 | -263 | 119 | 178 |
31 Mar 22 | 57 | -278 | 110 | 221 |
31 Dec 21 | 83 | -292 | 100 | 264 |
30 Sep 21 | 82 | -284 | 89 | 243 |
30 Jun 21 | 81 | -276 | 79 | 223 |
31 Mar 21 | 41 | -230 | 72 | 172 |
31 Dec 20 | 0 | -185 | 66 | 120 |
30 Sep 20 | 5 | -163 | 66 | 128 |
30 Jun 20 | 11 | -141 | 66 | 136 |
31 Mar 20 | 12 | -172 | 64 | 135 |
31 Dec 19 | 14 | -203 | 63 | 134 |
30 Sep 19 | 16 | -208 | 60 | 128 |
30 Jun 19 | 17 | -212 | 57 | 121 |
31 Mar 19 | 21 | -169 | 50 | 105 |
31 Dec 18 | 24 | -125 | 42 | 89 |
31 Dec 17 | 5 | -31 | 25 | 22 |
Quality Earnings: 2181 is currently unprofitable.
Growing Profit Margin: 2181 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2181 is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.2%).
Return on Equity
High ROE: 2181 has a negative Return on Equity (-63.27%), as it is currently unprofitable.